Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT03252431 is registered in ClinicalTrials.gov with EVIVE Biotechnology as lead sponsor.

NCT NCT03252431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03252431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Lead sponsor
EVIVE Biotechnology
Phase
Phase 3
Overall status
Completed
Start date
April 12, 2018
Completion date
March 5, 2020
Enrollment
393 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, neutropenia